Inhibrx Biosciences, Inc. INBX Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Inhibrx Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Inhibrx Biosciences, Inc.'s retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Inhibrx Biosciences, Inc.'s retained earnings?
- Inhibrx Biosciences, Inc. (INBX) reported retained earnings of -$279.63M in Q1 2026.
- How has Inhibrx Biosciences, Inc.'s retained earnings changed year-over-year?
- Inhibrx Biosciences, Inc.'s retained earnings decreased by 87.1% year-over-year, from -$149.44M to -$279.63M.
- What is the long-term trend for Inhibrx Biosciences, Inc.'s retained earnings?
- Over 2 years (2023 to 2025), Inhibrx Biosciences, Inc.'s retained earnings has grown at a -36.7% compound annual growth rate (CAGR), from -$613.73M to -$246.19M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.